04280AAC4

Arrowhead Pharmaceuticals, Inc.

Could not find a ticker for this position, may be a filing error

A developer of RNA-interference medicines that silence disease-causing genes, Arrowhead's first FDA-approved drug, REDEMPLO, treats a rare condition called familial chylomicronemia syndrome by lowering triglycerides. The company began in 1989 as Arrowhead Research Corporation, a tech incubator that commercialized university patents, before pivoting to gene-silencing medicines after buying Roche's RNAi assets in 2011. Its name was chosen to symbolize a focused, forward-moving direction.

Convertible Senior Notes due 2032 (0%)